Neuromod Devices
Neuromod Devices is an Irish medtech company that develops and commercializes Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus, sold through a certified network of audiology clinics across the US, Europe, and Canada.
- Company typePrivate
- Founded2010
- HeadquartersDublin, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neuromod Devices does
Neuromod Devices Ltd is an Irish medical technology company headquartered in Dublin that has developed Lenire, the first and only FDA-approved bimodal neuromodulation device for the treatment of tinnitus. Lenire combines simultaneous auditory stimulation via headphones with gentle electrical stimulation of the tongue to induce neuroplastic changes in the brain, with clinical evidence showing clinically significant symptom reduction in 81.8–91.5% of treated patients across trials and real-world cohorts involving 600+ subjects, supported by 136+ patents across 37 countries.
The company operates a single-product business model: it manufactures and sells the Lenire hardware device and associated treatment protocols exclusively through a certified network of audiology and ENT clinics. As of 2026, Lenire is available in more than 130 clinics staffed by over 200 clinicians across the USA, Europe, and newly launched Canada, with planned Australian entry in Q4 2026 and additional European launches in the Netherlands and Portugal. Revenue is generated through hardware sales to clinic partners, with the company providing clinical training, commercial enablement, and an all-in-one Partner Platform to support practice economics.
Neuromod has raised approximately €40 million across multiple rounds since 2010, with key institutional backers including Panakès Partners, Fountain Healthcare Partners, the European Investment Bank, and Enterprise Ireland. The company has scaled through a tightly executed regulatory-first strategy — FDA De Novo approval (March 2023), CE-Mark, Health Canada, ISO 13485, and TGA clearance — and is now in active commercial expansion across North America, Europe, and Oceania, supported by a lean 11–50 employee organization and a distributed commercial leadership team including a dedicated President of Global Commercial Operations and CEO of Neuromod USA.
Neuromod Devices firmographics
Firmographics- Name
- Neuromod Devices
- Legal name
- Neuromod Devices Ltd
- Website
- https://neuromoddevices.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neuromod Devices is an Irish medtech company that develops and commercializes Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus, sold through a certified network of audiology clinics across the US, Europe, and Canada.
- Ownership category
- akta.pro rank
Neuromod Devices industry classification
Industry- Product category
- Neuromodulation medical devices for tinnitus treatment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
Keywords
Where Neuromod Devices is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Neuromod Devices business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Lenire Tinnitus Treatment Device Sales: Neuromod generates revenue from the sale and distribution of its Lenire tinnitus treatment device through certified clinical providers and clinic partners across the USA, Europe, and Canada. The device is provided to tinnitus patients via clinical settings with supporting treatment protocols.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Neuromod Devices product offering
Product offeringCore offering
Neuromod Devices develops, manufactures, and distributes Lenire, the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. Lenire combines simultaneous auditory stimulation through headphones and gentle electrical stimulation to the tongue via a proprietary mouthpiece to deliver a 12-week at-home treatment protocol prescribed and supervised by trained audiologists at certified tinnitus treatment clinics. The company sells the device and associated Partner Platform support services to clinics rather than directly to consumers.
Product overview
Neuromod Devices offers a single unified core product, Lenire, which is the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. The device combines auditory stimulation through headphones with gentle tongue stimulation via a proprietary tongue tip to treat tinnitus. Lenire is supported by the largest body of evidence for any tinnitus-specific medical device, with over 136 neuromodulation patents across 37 countries and distribution through more than 130 clinics in the USA and Europe. The company provides an end-to-end Partner Platform for clinics that includes practice enablement, clinical and commercial training, and scalable onboarding support.
Differentiator
Problem solved
Functional benefit
Brands
- Lenire: FDA-approved bimodal neuromodulation tinnitus treatment device that combines auditory and tongue stimulation to provide treatment for tinnitus patients.
Products and services
- Lenire Tinnitus Treatment Device Lenire is the first and only FDA-approved bimodal neuromodulation device for tinnitus, combining simultaneous auditory stimulation via headphones and gentle tongue stimulation via a proprietary intra-oral tip. It is prescribed and supervised by trained audiologists at certified tinnitus treatment clinics as a 12-week at-home treatment course for adults with bothersome tinnitus. It is supported by three large-scale peer-reviewed clinical trials involving more than 600 patients.
- Tinnitus Masterclass Online Course An online educational course developed by Neuromod for audiologists and ENT specialists in Europe that combines medical, clinical, and commercial modules on tinnitus care, with the goal of expanding the pool of clinicians able to deliver Lenire treatment.
Quantifiable outcome
- 81.8% of 140 patients experienced clinically significant tinnitus reduction after 12 weeks of Lenire treatment
- +3 more outcomes
Companies that use Neuromod Devices
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles2 records
Neuromod Devices technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Neuromod Devices partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered supporting and minor.
- KPMGsupportingKPMG is listed as a partner on Neuromod's website, suggesting professional services or advisory support for the company's operations.
- BSIsupportingBSI (British Standards Institution) is listed as a partner, likely providing ISO certification and quality management standards support for Lenire's regulatory compliance.
- TomkinsminorTomkins is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.
- Shay GlennminorShay Glenn is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.
- Byrne WallaceminorByrne Wallace is listed as a partner logo on Neuromod's website, potentially providing legal advisory services for the Irish-headquartered company.
Scale indicators8 records
Recent moves9 records
Expansion highlights7 records
Neuromod Devices competitors and assessment
Company assessmentDirect peers
- Neuromonics: Australian medical device company that pioneered the Oasis tinnitus treatment device using customized acoustic stimulation; one of the closest direct competitors to Lenire in the clinic-delivered, device-based tinnitus treatment category.
- Otoharmonics (Levo System): Developer of the Levo tinnitus sound therapy system, a FDA-cleared personalized sound therapy device delivered through audiologists; competes with Lenire for the same clinician channel and tinnitus patient population.
- SoundCure (StimRouter / Serenade): Developed the Serenade tinnitus treatment device using custom sound therapy; another clinic-administered, FDA-cleared tinnitus therapy competing for the same audiologist customer base as Lenire.
Emerging players
- Desyncra: Markets Desyncra for tinnitus, a CR(r) neuromodulation therapy that pairs acoustic stimulation with electrical tongue stimulation, making it the closest mechanistic competitor to Lenire's bimodal neuromodulation approach.
Broad incumbents
- Sonova (Phonak): Global hearing aid leader whose Phonak brand offers tinnitus balance programs and sound therapy features integrated into hearing aids; competes via scale, audiologist relationships, and bundled solutions rather than dedicated tinnitus devices.
- WS Audiology (Widex / Signia): Owns the Widex and Signia hearing aid brands, both of which offer integrated tinnitus therapy features; represents a broad incumbent alternative that audiologists can choose instead of a dedicated tinnitus device like Lenire.
- GN Hearing (ReSound / Beltone): Major hearing aid manufacturer whose ReSound and Beltone brands include tinnitus sound therapy features and apps, providing an alternative path for tinnitus care within mainstream hearing aid fitting.
- Starkey Hearing Technologies: US-based hearing aid manufacturer offering tinnitus technology within its hearing aid lineup and patient apps, competing with Lenire for the same tinnitus-patient demand via existing hearing care channels.
Regional players
- Cochlear Limited: Australian-headquartered implantable hearing solutions company with growing tinnitus and hearing loss adjacencies; relevant as a regional peer given Neuromod's Australian expansion plans.
Others
- Cogito (behavioral health / digital therapeutics): While not a direct tinnitus competitor, behavioral and digital therapeutics for tinnitus (e.g., CBT-based apps) represent a non-device alternative category that audiologists and patients may choose instead of a clinic-based neuromodulation device.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Neuromod Devices social profiles
Digital presenceNeuromod Devices compliance and trust
Trust signalCompliance3 records
Neuromod Devices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neuromod Devices leadership team
Management profileNumber of profiles
Profiles7 records
Neuromod Devices funding detail
Funding detailFunding overview
Funding rounds8 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neuromod Devices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neuromod Devices
What does Neuromod Devices do?
Neuromod Devices develops, manufactures, and distributes Lenire, the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. Lenire combines simultaneous auditory stimulation through headphones and gentle electrical stimulation to the tongue via a proprietary mouthpiece to deliver a 12-week at-home treatment protocol prescribed and supervised by trained audiologists at certified tinnitus treatment clinics. The company sells the device and associated Partner Platform support services to clinics rather than directly to consumers.
Is Neuromod Devices a public or private company?
Neuromod Devices is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neuromod Devices founded?
Neuromod Devices was founded in 2010. It employs 11 to 50 people.
Where is Neuromod Devices based?
Neuromod Devices is headquartered in Dublin, Ireland, in the Europe region.
How does Neuromod Devices make money?
One revenue line is on record: lenire Tinnitus Treatment Device Sales.
Who are Neuromod Devices's main competitors?
Direct peers on record are Neuromonics, Otoharmonics (Levo System) and SoundCure (StimRouter / Serenade). Desyncra is listed as an emerging player. Broad incumbents are Sonova (Phonak), WS Audiology (Widex / Signia), GN Hearing (ReSound / Beltone) and Starkey Hearing Technologies. Cochlear Limited is listed as a regional player. Cogito (behavioral health / digital therapeutics) is listed as an others.
Does Neuromod Devices have an API?
No public API is recorded for Neuromod Devices.
What industry is Neuromod Devices in?
Neuromod Devices's product category is Neuromodulation medical devices for tinnitus treatment. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 334510 and its SIC code is 3845.